Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study

Conditions:   Hormone-receptor-positive Breast Cancer;   Premenopausal Breast Cancer;   Breast Cancer Patients at Intermediate to High Risk;   Ovarian Function Suppression Combined With Aromatase Inhibitor or Tamoxifen or Torimefen Interventions:   Drug: Aromatase inhibitor;   Procedure: ovarian function suppression (Oophorectomy, Ovarian irradiation, Gonadotropin-releasing hormone agonist);   Drug: Tamoxifen;   Drug: toremifene Sponsor:   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials